Severe acute respiratory syndrome (SARS): Lessons learnt in Hong Kong

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.2, 2013, Pages

  Hui, David S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Lessons; Management; Middle east respiratory syndrome (MERS); Severe acute respiratory syndrome (SARS)

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CARBON DIOXIDE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOMODULATING AGENT; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN;

CORONAVIRUS INFECTION; COUGHING; DISEASE TRANSMISSION; ENDOTRACHEAL INTUBATION; FACE MASK; HEALTH CARE PERSONNEL; HONG KONG; HUMAN; INFECTION CONTROL; LUNG INJURY; MANUAL VENTILATION; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; NONINVASIVE VENTILATION; OXYGEN THERAPY; RESPIRATORY TRACT INFECTION; RESUSCITATION; REVIEW; RISK FACTOR; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRACHEOTOMY; VIRUS LOAD; WARD;

EID: 84891144308     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.06.18     Document Type: Review

References (52)

1. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003;362:1353-8.
2. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
3. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
4. WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available online: http://www.who.int/csr/sars/country/table2003_09_23/en
5. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
6. Cheng VC, Tang BS, Wu AK, et al. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect 2004;49:262-73.
7. Hui DS, Wong KT, Antonio GE, et al. Severe acute respiratory syndrome: correlation between clinical outcome and radiologic features. Radiology 2004;233:579-85.
8. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003;124:12-5.
9. Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005;11:1860-5.
10. Che XY, Di B, Zhao GP, et al. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis 2006;43:e1-5.
11. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
12. Memish ZA, Zumla AI, Al-Hakeem RF, et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487-94.
13. Guery B, Poissy J, El Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013;381:2265-72.
14. Wong RS, Hui DS. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004;10:339-41.
15. Wong BC, Lee N, Li Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis 2010;51:1176-83.
16. Hui DS, Chow BK, Chu L, et al. Exhaled air dispersion and removal is influenced by isolation room size and ventilation settings during oxygen delivery via nasal cannula. Respirology 2011;16:1005-13.
17. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9:713-7.
18. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and shortterm outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9.
19. Yu IT, Xie ZH, Tsoi KK, et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others? Clin Infect Dis 2007;44:1017-25.
20. Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012;7:e35797.
21. Hui DS, Hall SD, Chan MT, et al. Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest 2006;130:730-40.
22. Hui DS, Ip M, Tang JW, et al. Airflows around oxygen masks: A potential source of infection? Chest 2006;130:822-6.
23. Hui DS, Hall SD, Chan MT, et al. Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest 2007;132:540-6.
24. Hui DS, Chow BK, Chu LC, et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009;135:648-54.
25. Hui DS, Chow BK, Ng SS, et al. Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest 2009;136:998-1005.
26. Chan MT, Chow BK, Chu L, et al. Mask ventilation and dispersion of exhaled air. Am J Respir Crit Care Med 2013;187:e12-4.
27. Hui DS, Chow BK, Chu L, et al. Exhaled air dispersion during coughing with and without wearing a surgical or N95 mask. PLoS One 2012;7:e50845.
28. Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004;10:581-6.
29. Ströher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004;189:1164-7.
30. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414-20.
31. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
32. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.
33. Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet 2003;362:293-4.
34. Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10:317-9.
35. Sainz B Jr, Mossel EC, Peters CJ, et al. Interferon-beta and interferongamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004;329:11-7.
36. Morgenstern B, Michaelis M, Baer PC, et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005;326:905-8.
37. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69-75.
38. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10:290-3.
39. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290:3222-8.
40. Wong KT, Antonio GE, Hui DS, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003;228:395-400.
41. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004;57:260-5.
42. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.
43. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005;171:850-7.
44. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003;9:1381-7.
45. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507-8.
46. Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004;59:602-8.
47. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005;235:168-75.
48. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31:304-9.
49. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10:676-8.
50. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-6.
51. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447-56.
52. Hui DS, Lee N, Chan PK. et al. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 2013;98:410-6.